| scholarly article | Q13442814 |
| P50 | author | Ronald W Busuttil | Q87949429 |
| P2093 | author name string | Rafik M Ghobrial | |
| John P Duffy | |||
| Jonathan R Hiatt | |||
| David S K Lu | |||
| Douglas G Farmer | |||
| Hasan Yersiz | |||
| Charles Lassman | |||
| Myron J Tong | |||
| Elizabeth Benjamin | |||
| Gerald Lipshutz | |||
| Andrew Vardanian | |||
| Melissa Watson | |||
| P2860 | cites work | Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma | Q24540058 |
| A model to predict survival in patients with end-stage liver disease | Q28199900 | ||
| Hepatocellular carcinoma | Q29615841 | ||
| Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis | Q29619508 | ||
| Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. | Q34564910 | ||
| The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma | Q35648702 | ||
| Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma | Q35891275 | ||
| Hepatocellular carcinoma: recent trends in the United States | Q35929212 | ||
| Should we biopsy each liver mass suspicious for hepatocellular carcinoma before liver transplantation?--yes | Q36236048 | ||
| Chronic viral hepatitis and hepatocellular carcinoma | Q36794392 | ||
| Projecting future complications of chronic hepatitis C in the United States | Q40594872 | ||
| Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria | Q40637196 | ||
| The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981-1991. | Q41870269 | ||
| Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients | Q41968480 | ||
| Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation | Q42612881 | ||
| Liver transplantation for hepatocellular carcinoma: the MELD impact. | Q42618817 | ||
| Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. | Q42630836 | ||
| Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study | Q42638599 | ||
| Hepatic resection versus transplantation for hepatocellular carcinoma | Q43946793 | ||
| Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients | Q44498208 | ||
| Liver transplantation for small hepatocellular carcinoma in cirrhosis: analysis of our experience | Q44550508 | ||
| The first 100 liver transplants at UCLA. | Q44791634 | ||
| Liver transplantation in the MELD era: a single-center experience | Q44950548 | ||
| Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan | Q45258006 | ||
| Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? | Q45969854 | ||
| Liver transplantation for hepatocellular carcinoma in patients beyond the Milan but within the UCSF criteria | Q46079440 | ||
| Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience | Q46132760 | ||
| The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma | Q46286499 | ||
| A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation | Q46540011 | ||
| Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival | Q46743120 | ||
| Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. | Q46918054 | ||
| Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. | Q46971158 | ||
| Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome | Q47240294 | ||
| Survival after liver transplantation for hepatocellular carcinoma | Q49151135 | ||
| Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. | Q51538099 | ||
| Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. | Q52966926 | ||
| Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. | Q53350866 | ||
| Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power | Q57757276 | ||
| Predictive Factors of Outcome After Liver Transplantation in Patients With Cirrhosis and Hepatocellular Carcinoma | Q60198990 | ||
| Predictors of Long-Term Survival After Liver Transplantation for Hepatocellular Carcinoma | Q61651013 | ||
| Orthotopic liver transplantation: treatment of choice in cirrhotic patients with hepatocellular carcinoma? | Q72003680 | ||
| Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies | Q73490475 | ||
| Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival | Q73576933 | ||
| Liver organ allocation for hepatocellular carcinoma: are we sure? | Q73576939 | ||
| Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles | Q74280205 | ||
| Rising incidence of hepatocellular carcinoma in the United States | Q74595692 | ||
| Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters | Q77847343 | ||
| The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin | Q79832866 | ||
| Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis | Q79834757 | ||
| Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation | Q81668582 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| liver transplantation | Q1368191 | ||
| P304 | page(s) | 502-9; discussion 509-11 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Annals of Surgery | Q4767866 |
| P1476 | title | Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA | |
| P478 | volume | 246 |
| Q42064611 | A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma |
| Q36302710 | A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma |
| Q44597163 | A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria |
| Q42004327 | Accomplishments in 2007 in the management of hepatobiliary cancers. |
| Q41531360 | Advances and Future Directions in the Treatment of Hepatocellular Carcinoma |
| Q36728731 | Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria |
| Q46257390 | Apurinic apyrimidinic endonuclease/redox effector factor 1 immunoreactivity and grading in hepatocellular carcinoma risk of relapse after liver transplantation |
| Q47160952 | Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation |
| Q51063349 | BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. |
| Q64241675 | Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results |
| Q37636484 | Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis |
| Q38269467 | Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation |
| Q46245132 | Bone metastases from hepatocellular carcinoma: clinical features and prognostic factors |
| Q39141900 | Bridging locoregional therapy: Longitudinal trends and outcomes in patients with hepatocellular carcinoma |
| Q46012768 | CT and MRI Improve Detection of Hepatocellular Carcinoma, Compared With Ultrasound Alone, in Patients With Cirrhosis |
| Q39049991 | Can response to locoregional therapy help predict long-term survival after liver transplantation for hepatocellular carcinoma? A systematic review |
| Q88581876 | Changing Paradigm in the Surgical Management of Hepatocellular Carcinoma With Salvage Transplantation |
| Q34080277 | Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation |
| Q42252781 | Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma |
| Q40707301 | Clinicopathologic study on complications of orthotopic liver transplantation in 54 patients with chronic hepatitis B viral infection |
| Q41544681 | Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma". |
| Q50801877 | Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria. |
| Q46170972 | Complete tumor encapsulation on magnetic resonance imaging: a potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma |
| Q26740332 | Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma |
| Q89623916 | Controversies in the management of hepatocellular carcinoma |
| Q26740375 | Current Treatment Approaches to HCC with a Special Consideration to Transplantation |
| Q37769279 | Current controversies surrounding liver transplantation for hepatocellular carcinoma |
| Q87604943 | Current management of hepatocellular carcinoma |
| Q38417397 | Current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation |
| Q38266862 | Current surgical treatment strategies for hepatocellular carcinoma in North America |
| Q46093050 | Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection |
| Q39118972 | Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma |
| Q38762988 | Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis |
| Q43262772 | Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma? |
| Q83394437 | Down-staging of hepatocellular carcinoma prior to liver transplantation: the power of selection |
| Q36733226 | Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria |
| Q43666308 | Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. |
| Q56967787 | Evolutionary Distance Predicts Recurrence After Liver Transplantation in Multifocal Hepatocellular Carcinoma |
| Q38585074 | Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest |
| Q34080984 | Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis |
| Q57167305 | Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions |
| Q83627763 | Extended criteria for living donor liver transplantation in patients with advanced hepatocellular carcinoma |
| Q37323728 | HCC patients suffer less from geographic differences in organ availability |
| Q37980015 | HCC: current surgical treatment concepts |
| Q83498126 | Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus |
| Q64228213 | Hepatitis B and hepatocellular carcinoma recurrence after living donor liver transplantation: The role of the Milan criteria |
| Q58021316 | Hepatocellular Carcinoma |
| Q92477187 | Hepatocellular Carcinoma and Liver Transplantation: A Single-Center Experience |
| Q29994588 | Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices |
| Q48268747 | Hepatocellular Carcinoma: Surgical Management and Evolving Therapies |
| Q42333017 | Hepatocellular carcinoma (HCC) recurrence and what to do when it happens |
| Q38604896 | Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient |
| Q35626757 | Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome |
| Q38368606 | Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection |
| Q33881131 | Hepatocellular carcinoma: early-stage management challenges |
| Q36171275 | Hepatocellular carcinoma: natural history, current management, and emerging tools |
| Q34409128 | Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. |
| Q88791892 | Hepatocellular carcinoma: when is liver transplantation oncologically futile? |
| Q35631295 | Hong Kong consensus recommendations on the management of hepatocellular carcinoma |
| Q43778834 | Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. |
| Q35207762 | Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. |
| Q30596607 | Increasing survival of hepatocellular carcinoma patients in Scotland: a review of national cancer registry data |
| Q42207243 | Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status |
| Q37795703 | Is it time to reconsider the BCLC/AASLD therapeutic flow‐chart? |
| Q39371292 | LI-RADS and transplantation for hepatocellular carcinoma |
| Q37579484 | LIVER TRANSPLANTATION FOR CARCINOMA HEPATOCELLULAR IN SÃO PAULO: 414 CASES BY THE MILAN/BRAZIL CRITERIA. |
| Q30276330 | Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria |
| Q91795139 | Liver Transplantation Beyond Milan Criteria |
| Q89987746 | Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria |
| Q63367353 | Liver Transplantation for Hepatocellular Carcinoma |
| Q36962089 | Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome |
| Q39396746 | Liver Transplantation for Hepatocellular Carcinoma: "Experience of Memorial Sisli Hospital". |
| Q36532133 | Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience |
| Q92700875 | Liver Transplantation from Voluntary Organ Donor System in China: A Comparison between DBD and DCD Liver Transplants |
| Q38046482 | Liver transplantation and expanded Milan criteria: does it really work? |
| Q38519906 | Liver transplantation as a management of hepatocellular carcinoma |
| Q47325009 | Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma |
| Q37626584 | Liver transplantation for HCC: its role: Eastern and Western perspectives |
| Q30452202 | Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions |
| Q27021650 | Liver transplantation for hepatic tumors: a systematic review |
| Q84950960 | Liver transplantation for hepatocellular carcinoma |
| Q86868938 | Liver transplantation for hepatocellular carcinoma |
| Q26750463 | Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review |
| Q37140667 | Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies |
| Q39739700 | Liver transplantation for hepatocellular carcinoma: an update. |
| Q36702287 | Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. |
| Q40830408 | Liver transplantation for hepatocellular carcinoma: is zero recurrence theoretically possible? |
| Q38211859 | Liver transplantation for hepatocellular carcinoma: past, present and future |
| Q64249297 | Liver transplantation for hepatocellular carcinoma: pushing the boundaries |
| Q42349921 | Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. |
| Q37777111 | Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature |
| Q36220176 | Liver transplantation in adults: Choosing the appropriate timing |
| Q43787353 | Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience |
| Q34976928 | Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China |
| Q38878205 | Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma |
| Q36643551 | Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria |
| Q59359137 | Living Donor Liver Transplantation Using Small-for-Size Grafts: Does Size Really Matter? |
| Q28073611 | Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes |
| Q37972811 | Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience |
| Q36063276 | Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis |
| Q84694311 | Long-term outcomes following aggressive management of recurrent hepatocellular carcinoma after upfront liver resection |
| Q35194675 | Major challenges limiting liver transplantation in the United States. |
| Q36088854 | Management and prevention of post-transplant malignancies in kidney transplant recipients |
| Q28258769 | Management of HCC |
| Q35771842 | Management of Hepatocellular Carcinoma: Current Status and Future Directions |
| Q37625446 | Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. |
| Q42322512 | Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States |
| Q42333014 | Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma |
| Q37639624 | Model for End Stage Liver Disease and hepatocellular carcinoma: a moving target |
| Q42610253 | Molecular classification and clonal differentiation of hepatocellular carcinoma: the step forward for patient selection for liver transplantation. |
| Q47682080 | Molecular markers and hepatocellular carcinoma: lending a helping hand in liver transplantation? |
| Q83304872 | Monday blues of deceased-donor liver transplantation |
| Q35703937 | NCCN clinical practice guidelines in oncology: hepatobiliary cancers |
| Q37000692 | National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. |
| Q37696382 | Nationwide population-based study reveals increased malignancy risk in taiwanese liver transplant recipients |
| Q37378982 | Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation |
| Q38035612 | New concepts and best practices for management of pre- and post-transplantation cancer. |
| Q46046878 | Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma. |
| Q46844548 | Outcome comparisons among the Hangzhou, Chengdu, and UCSF criteria for hepatocellular carcinoma liver transplantation after successful downstaging therapies |
| Q51747220 | Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma |
| Q83769665 | Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation |
| Q38485998 | Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation? |
| Q57812166 | Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients |
| Q37341959 | Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis |
| Q89444399 | Preoperative computed tomography and serum α-fetoprotein to predict microvascular invasion in hepatocellular carcinoma |
| Q50195636 | Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma |
| Q41851468 | Primary liver transplantation vs liver resection followed by transplantation for transplantable hepatocellular carcinoma: Liver functional quality and tumor characteristics matter |
| Q42237455 | Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. |
| Q46129535 | Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database |
| Q38262115 | Recent advances in the surgical treatment of hepatocellular carcinoma |
| Q40434294 | Recurrent Hepatocellular Carcinoma After Liver Transplantation: Analysis of Risk Factors. |
| Q38594974 | Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient |
| Q51730283 | Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with HALTHCC improves ablate and wait strategy. |
| Q34038193 | Retracted: A Scoring Model Based on Neutrophil to Lymphocyte Ratio Predicts Recurrence of HBV-Associated Hepatocellular Carcinoma after Liver Transplantation |
| Q38243059 | Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria |
| Q44490029 | Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis |
| Q37928952 | Role of organ transplantation in the treatment of malignancies: hepatocellular carcinoma as the most common tumour treated with transplantation. |
| Q39587556 | Routinely reported 'equivocal' lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. |
| Q33408291 | Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation |
| Q34473754 | Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection |
| Q26771246 | Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future |
| Q92068027 | Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma |
| Q39223475 | Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study |
| Q46187843 | Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria |
| Q27005375 | Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation |
| Q37376515 | Successful resection of hepatocellular cancer not amenable to Milan criteria and durable complete remission induced by systemic polichemotherapy after development of metastases - should we think about revising the current treatment guidelines in sel |
| Q37900264 | Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement |
| Q54989355 | Surgical Treatment of Hepatocellular Carcinoma. |
| Q35166162 | Surgical treatment for hepatocellular carcinoma |
| Q37373016 | Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy |
| Q38006772 | Surgical treatment for large hepatocellular carcinoma: does size matter? |
| Q37768895 | Surgical treatment of hepatocellular cancer: expert consensus conference |
| Q43230110 | Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic |
| Q42177882 | Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion |
| Q33913779 | Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. |
| Q37995306 | Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma |
| Q35634422 | Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report |
| Q38217657 | The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. |
| Q43805781 | The difference and the transition of indication for adult living donor liver transplantation between the West and the East |
| Q37093639 | The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). |
| Q34868567 | The impact of liver transplantation after surgical treatment of hepatocellular carcinoma |
| Q93088176 | The power of tumor sizes in predicting the survival of solitary hepatocellular carcinoma patients |
| Q38181127 | The role of bridging therapy in hepatocellular carcinoma |
| Q39319551 | The role of liver cancer stem cells in donor liver allocation for patients with hepatocellular carcinoma |
| Q43026378 | Thrombosis after liver transplantation for hepatocellular carcinoma |
| Q46576223 | Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria |
| Q90704925 | Transplantation for Hepatocellular Carcinoma: Is There a Tumor Size Limit? |
| Q64062234 | Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach |
| Q38549768 | Treatment of Liver Cancer |
| Q38295870 | Treatment of hepatocellular carcinoma: beyond international guidelines. |
| Q33661046 | Value of radiofrequency ablation in the treatment of hepatocellular carcinoma |
| Q46456307 | Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". |
| Q37876384 | Which matters most: number of tumors, size of the largest tumor, or total tumor volume? |
| Q27691331 | [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma |
| Q79946062 | [Combined therapies including interventional radiology] |
Search more.